九强生物收盘下跌2.55%，滚动市盈率17.65倍，总市值87.42亿元

Core Viewpoint - The company Jiukang Bio is experiencing a decline in stock price and financial performance, with a significant drop in revenue and net profit compared to the previous year, while its valuation remains low compared to the industry average [1][2]. Company Summary - Jiukang Bio's closing stock price on August 14 was 14.91 yuan, down 2.55%, with a rolling PE ratio of 17.65 times and a total market capitalization of 8.742 billion yuan [1]. - The company operates in the medical device industry, focusing on biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics [1]. - Jiukang Bio's main products include in vitro diagnostic reagents, in vitro testing instruments, instrument leasing, inspection services, and laboratory auxiliary services [1]. - The company was recognized as a "National Enterprise Technology Center" on February 22, 2023, as part of the 29th batch of newly recognized national enterprise technology centers [1]. Financial Performance - In the first quarter of 2025, Jiukang Bio reported operating revenue of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99% year-on-year, with a gross profit margin of 80.84% [1]. Industry Comparison - The average PE ratio for the medical device industry is 55.76 times, with a median of 39.14 times, positioning Jiukang Bio at 38th place within the industry [1][2]. - The company’s PE ratio is significantly lower than the industry average, indicating potential undervaluation [2].